| ²é¿´: 738 | »Ø¸´: 3 | ||
hippo-rdͳæ (СÓÐÃûÆø)
|
[ÇóÖú]
ÄÄλ¸ßÊÖ¿´¿´Õâ¸ö±à¼µÄÒâ¼û ÒÑÓÐ3È˲ÎÓë
|
|
Dear Prof. D, I write you in regards to Manuscript ID DTA-14-0252 entitled "*** reductase decrease the systemic exposure of*** in rats" which you submitted to Drug Testing and Analysis. Your manuscript underwent editorial review and the quality and relevance of your work was much appreciated. Your comment that this work falls into the scope of DTA is well received but I am sorry to inform you that the editorial board did not uniformly share this opinion. There is sound analytical work to determine both the reduced and the oxidized form of rifampicin and comprehensive data on administration studies; however, since these are more of clinical/medicinal value, other journals focused and dedicated to such work are recommended. The Journal is convinced that your submission is of high scientific standard, but DTA might not be the adequate venue for it as appropriate reviews of your work should be provided to ensure fair peer-review processes. Hence, your manuscript was denied publication in Drug Testing & Analysis. Thank you for considering this Journal for the publication of your research. I hope the outcome of this specific submission will not discourage you from submitting future manuscripts. Sincerely, ÕâÆªÂÛÎÄÊÇͨ¹ý²â¶¨ÑªÒ©Å¨¶ÈµÄ·½·¨·¢ÏÖÒ»¸ö¶¾Àí»úÖÆ¡£¸ÄͶÓÐʲôÔÓÖ¾ÍÆ¼öÂ𣿠|
» ²ÂÄãϲ»¶
ÄϾ©´óѧ»¯Ñ§µ÷¼Á
ÒѾÓÐ11È˻ظ´
²ÄÁÏר˶µ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸»ª¶«Ê¦·¶´óѧÓлú»¯Ñ§×¨Òµ£¬³õÊÔ351·Ö£¬¸´ÊÔ±»Ë¢Çóµ÷¼Á!
ÒѾÓÐ5È˻ظ´
283Çóµ÷¼Á£¨080500£©
ÒѾÓÐ7È˻ظ´
311Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
275Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
¸÷λÀÏʦºÃ£¬ÎÒµÄһ־ԸΪ±±¾©¿Æ¼¼´óѧ085601²ÄÁÏר˶
ÒѾÓÐ9È˻ظ´
294·Ö080500²ÄÁÏ¿ÆÑ§Ó빤³ÌÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸±±¾©¹¤Òµ´óѧ£¬324·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸Î人Àí¹¤£¬×Ü·Ö321£¬Ó¢Ò»Êý¶þ£¬ÇóÀÏʦÊÕÁô¡£
ÒѾÓÐ11È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
´ó¼Ò°ïÎÒ¿´Ò»Ï Õâ¾ä»°µÄÀí½â¶Ô²»¶Ô
ÒѾÓÐ8È˻ظ´
´ó¼Ò½øÀ´°ïÎÒ¿´Ò»¿´£¬Ö÷±à¸´ÉóµÄÒâ˼¾¿¾¹ÈçºÎ£¡
ÒѾÓÐ8È˻ظ´
ÎÒµÄÕâ¸öÉó¸åÒâ¼ûÊÇʲôÒâ˼°¡£¿Ð»Ð»
ÒѾÓÐ4È˻ظ´
ÂÛÎijõÉóÒâ¼û»ØÀ´£¬µ«Ã»Óп´¶®ÊÇʲôÒâ˼£¬Çë´ó¼Ò°ïæָµã¸öÏ£¬Ð»Ð»£¡
ÒѾÓÐ8È˻ظ´
±à¼Ìá³öµÄÐÞ¸ÄÒâ¼ûÓе㿴²»Ì«¶®°¡£¬ÇóÖîλ´óÉñ¸øµãÒâ¼û£¬¶àл£¡£¡
ÒѾÓÐ4È˻ظ´
ÕâÊÇʲôÒâ˼°¡£¿ÎÒÐèÒªÔÙͶô?
ÒѾÓÐ5È˻ظ´
Ͷ¸åºóÐÞ¸ÄÒâ¼û»ØÀ´£¬µ«ÓÐÒ»Ìõû¿´Ã÷°×£¬Çë¸ßÊÖÖ¸½Ì
ÒѾÓÐ13È˻ظ´
ÎÄÕÂÒÑÊÕ£¬´ó¼Ò°ïæ¿´¿´±à¼²¿·µ»ØµÄÐÞ¸ÄÒâ¼û£¿
ÒѾÓÐ14È˻ظ´
´ó¼ÒÇë°ïÎÒ¿´¿´Õâ¸öÉó¸åÒâ¼ûÊÇʲôÒâ˼£¿
ÒѾÓÐ7È˻ظ´
¿´¿´µç¹¤¼¼Êõѧ±¨¸øÎÒµÄÉó¸åÒâ¼û
ÒѾÓÐ3È˻ظ´
ÕâÌõÐÞ¸ÄÒâ¼û²»ºÃ¸Ä°¡
ÒѾÓÐ13È˻ظ´
Çë°ïæ¿´¿´Éó¸åÈËдµÄÉó¸åÒâ¼ûÊÇʲôÒâ˼°¡£¿
ÒѾÓÐ8È˻ظ´
JPC¾Ý¸å£¬´ó¼Ò°ïæ¿´¿´Òâ¼û£¬Èç¹ûÊʵ±Ð޸ĿÉÒÔÔÙͶÄÄЩÆÚ¿¯£¿
ÒѾÓÐ80È˻ظ´
ÖÐÎÄÆÚ¿¯ÐÞ¸ÄÒâ¼ûµÄ»Ø¸´
ÒѾÓÐ10È˻ظ´
ÇëÎÊÕâÌõproofÖеÄÐÞ¸ÄÒâ¼ûÊÇʲôÒâ˼£¿£¿ bigcup...
ÒѾÓÐ7È˻ظ´
Çë½ÌÉó¸åÈËËùÌáÒâ¼ûµÄÒâ˼
ÒѾÓÐ4È˻ظ´
´ó¼Ò¸ø¿´¿´Õâ¸ö±à¼²¿µÄÒâ¼û£¬Ö¸µ¼Ò»ÏÂÎÒÕâ¸öÐÂÊÖ
ÒѾÓÐ7È˻ظ´
ÂÛÎÄÐ޻غó±à¼¸ø³öÈçÏÂÒâ¼û£¬ÓÐЩ¿´²»¶®Ê²Ã´Òâ˼£¬Ö¸¸ßÈËÖ¸µã
ÒѾÓÐ25È˻ظ´
°ï¿´¿´es&t Éó¸åÒâ¼û
ÒѾÓÐ22È˻ظ´
°ïÎÒ¿´¿´Õâ¸öArtwork Quality Results ÊÇʲôÒâ˼£¿
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿ËÄܰïÎÒ¿´¿´Õâ¸ö¸Ö½îÊÇʲôÐͺÅ
ÒѾÓÐ4È˻ظ´
JPCC »Ø¸´ÁË £¬ÈçÏ£¬ÈÃÎÒÑ¡±à¼£¬Çë´óÏÀ¿´¿´ÊÇʲôÒâ˼£¿
ÒѾÓÐ18È˻ظ´
jinladan1987
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 38 (СѧÉú)
- ½ð±Ò: 1378.9
- É¢½ð: 2742
- ºì»¨: 20
- Ìû×Ó: 1446
- ÔÚÏß: 913.4Сʱ
- ³æºÅ: 1911181
- ×¢²á: 2012-07-26
- ÐÔ±ð: GG
- רҵ: ¸ÅÂÊÂÛÓëËæ»ú·ÖÎö

2Â¥2014-09-05 08:45:17
zhenwuhuang
ÖÁ×ðľ³æ (ÎÄѧ̩¶·)
- Ó¦Öú: 4351 (¸±½ÌÊÚ)
- ½ð±Ò: 10181.3
- É¢½ð: 1
- ºì»¨: 137
- Ìû×Ó: 65926
- ÔÚÏß: 2433.9Сʱ
- ³æºÅ: 2227382
- ×¢²á: 2013-01-07
- ÐÔ±ð: GG
- רҵ: ÈËÀàÓªÑø
3Â¥2014-09-05 09:01:45
×Ô˽µÄè1988
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 4800 (¸±½ÌÊÚ)
- ¹ó±ö: 6.746
- ½ð±Ò: 50040.4
- É¢½ð: 11517
- ºì»¨: 256
- ɳ·¢: 134
- Ìû×Ó: 11684
- ÔÚÏß: 1473.7Сʱ
- ³æºÅ: 2004083
- ×¢²á: 2012-09-16
- ÐÔ±ð: GG
- רҵ: Óлú·Ö×Ó¹¦ÄܲÄÁÏ»¯Ñ§
- ¹ÜϽ: ÂÛÎÄͶ¸å
4Â¥2014-09-05 12:19:56














»Ø¸´´ËÂ¥